Trial
NCT00964990
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators
—
Condition
Pain
Intervention
JNJ-42160443
Why stopped
Logistic reasons associated with the FDA-imposed clinical hold.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-02